Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Johnson & Johnson →

  U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer

  • P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Mon 00:50
  • Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Sun 04:04

Related events

• JNJ secured marketing authorization from the U.S. FDA, and its Ottava platform challenges ISRG's market dominance.Jul 24
• Johnson & Johnson highlighted growth opportunities within the MedTech sector.Sep 10
• BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.Jun 7
• Experimental therapies require approval from the FDA.Sep 21
• Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.Jun 11